Purple Biotech Ltd. (PPBT) - Form 20-F Summary
Business Context and Reporting Period
Company: Purple Biotech Ltd.
Reporting Period: Fiscal year ended December 31, 2024.
Business Overview: Purple Biotech is a clinical-stage biotechnology company developing first-in-class oncology therapies. Its pipeline includes CM24 (a humanized monoclonal antibody targeting CEACAM1), NT219 (a small molecule dual inhibitor of IRS1/2 and STAT3), and the CAPTN-3 tribody platform with lead candidate IM1240. The company has no commercial revenue and relies on equity financing and potential out-licensing to fund operations.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (USD '000s) | 2023 (USD '000s) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(7,279) | $(19,977) |
| Operating Loss | $(11,005) | $(22,271) |
| Adjusted Operating Loss (Non-IFRS) | $(10,423) | $(20,396) |
| Research & Development Expenses | $(7,620) | $(17,034) |
| Selling, General & Admin Expenses | $(3,183) | $(5,237) |
| Cash and Cash Equivalents (End of Period) | $7,401 | $14,489 |
| Total Assets | $37,038 | $44,302 |
| Accumulated Deficit | $(144,693) | $(137,453) |
Material Changes vs. Prior Period
- Reduced Operating Loss: Net loss decreased by approximately 63% (from $20.0M to $7.3M) and operating loss decreased by 51% (from $22.3M to $11.0M). This improvement was primarily driven by a 55% reduction in R&D expenses due to the conclusion of the Phase 2 study for CM24.
- Financing Activity: The company raised approximately $6.8 million in net proceeds during 2024 through a registered direct offering ($2.5M net), a warrant inducement transaction ($1.8M net), and its At-The-Market (ATM) program ($2.85M net).
- ADS Ratio Change: Effective September 17, 2024, the company changed the ADS ratio from 1:10 to 1:200 (one ADS representing 200 ordinary shares) to regain compliance with NASDAQ minimum bid price requirements.
- Impairment: The company recorded a $202,000 impairment loss related to the decision to dissolve its Swiss subsidiary, Purple Biotech GmbH.
Guidance, Outlook, and Risks
- Clinical Outlook:
- CM24: Final data from the randomized Phase 2 study in pancreatic cancer (reported Dec 2024) showed consistent improvement in efficacy endpoints. A 3-arm Phase 2b study is planned for initiation in the second half of 2025.
- NT219: An investigator-initiated Phase 2 study for head and neck cancer is expected to initiate in the first half of 2025.
- IM1240: Pre-IND meeting with the FDA was held in 2024; IND submission is expected in 2026.
- Liquidity: As of December 31, 2024, the company held approximately $8.2 million in cash, cash equivalents, and short-term deposits. Management believes this is sufficient for at least the next 12 months but will require additional capital to continue development.
- Key Risks:
- Capital Requirements: Failure to raise additional capital could force the company to delay or eliminate development programs.
- Geopolitical Instability: Operations are based in Israel. While no material disruption has occurred to date, prolonged conflict could impact operations, supply chains, and capital raising.
- Regulatory Approval: No therapeutic candidates have been approved; clinical trials may fail to demonstrate safety or efficacy.
- Intellectual Property: Reliance on licensed technology (Yissum, THM) and potential infringement claims.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $8.2M cash balance against the projected burn rate for the upcoming Phase 2b and Phase 2 studies.
- CM24 Phase 2b Design: Review the specific inclusion criteria and endpoints for the planned Phase 2b study to assess the likelihood of regulatory success.
- Financing Terms: Examine the terms of the new warrants issued in the July 2024 inducement transaction and the December 2024 offering for potential dilution.
- Geopolitical Exposure: Assess the specific impact of the ongoing conflict in Israel on the company's third-party manufacturers and CROs.
- IIA Obligations: Review the contingent royalty obligations to the Israel Innovation Authority (IIA) regarding the NT219 asset, which could impact future exit proceeds.